CorMedix Beats Q3 Revenue Estimates but Suspends 2027 DefenCath Guidance
CRMD is trading near its 52-week low of $5.1 (2.9% above the low).
Summary
CorMedix posted Q3 2026 consolidated revenue of $54.5 million, above the $51.2 million street consensus, helped by higher sales from the acquired Melinta portfolio, but the quarter still produced a $14.7 million net loss and just $3.1 million of adjusted EBITDA versus $71.9 million a year ago. DefenCath contributed $17.2 million of net revenue, helped by a $5.0 million favorable change in sales-allowance estimate, as post-TDAPA pricing pressure took hold after the July 1 transition. Management suspended previously issued 2027 DefenCath revenue guidance, citing recently announced changes to the CMS reimbursement framework, and will not revisit it until early 2027. Full-year 2026 revenue guidance was maintained at $325-$345 million, adjusted EBITDA narrowed to $130-$140 million, and cash-based OpEx trimmed to $140-$145 million. Cash stood at $355.2 million at September 30, and the company lined up a term loan of up to $150 million, expecting to draw $75 million at the Heron asset acquisition closing, anticipated in Q1 2027. The REZZAYO prophylaxis sNDA has a PDUFA date in Q1 2027.
At the time of this announcement, CRMD was trading at $5.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.1M. The 52-week trading range was $5.10 to $13.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.